Skip to main content

Table 5 Treatment-related toxicity

From: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer

Toxicity

Weekly docetaxel

(n = 41)

3-weekly docetaxel

(n = 41)

P-value

 

No.

%

No.

%

 

Nausea

3

7

5

12

0.71

Vomiting

3

7

2

5

1.00

Stomatitis

3

7

4

10

1.00

Asthenia

4

10

7

17

0.33

Neuropathy

0

0

16

38.2

0.008

Peripheral oedema

5

12

12

29

0.57

Epiphora (tearing)

13

32

8

20

0.21

Nail problems

9

22

15

37

0.15